Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes, a test-negative study in Quebec, Canada - PubMed
7 hours ago
- #RSV
- #Nirsevimab
- #Immunization
- Quebec implemented a universally publicly funded infant nirsevimab program in 2024-25.
- Nirsevimab showed 86% effectiveness against ER consultations and 89% against hospitalizations due to RSV.
- Effectiveness was higher for preterm infants (93%) compared to those with chronic diseases (79%).
- 41 at-birth and 58 catch-up immunizations were needed to avert one RSV-associated hospitalization.
- 72% of RSV-associated hospitalizations were prevented in the at-birth group, and 59% in the catch-up group.
- Hypothetical 90% coverage by October could increase prevention to 82%.
- Nirsevimab is highly effective and could significantly reduce RSV burden with broad and timely administration.